Clinical trials: Hyperparathyroidism; Secondary, Renal
CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism
The Longitudinal PTH-Study
The main study aim is to quantify the agreement between the analytical results provided by two third generation and two second generation Parathyroid hormone (PTH) assays.
- Conditions
- CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Secondary Hyperparathyroidism, Kidney Replacement
- Trial name
- NCT03464149
- Testing
- One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)
- Where
- Austria
- Volunteers
- 132 people
- Sponsor
- Medical University of Vienna
Chronic Kidney Diseases
SOP's for CKD-MBD-Biomarkers
CKD-MBD (Chronic Kidney Disease - Mineral and Bone Disorder) is an extensive disease and includes dysfunction of the mineral metabolism, the bone metabolism and cardiovascular diseases in the context of renal insufficiency.
- Trial name
- NCT02708368
- Testing
- blood withdrawal
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Secondary Hyperparathyroidism, Disorder Related to Renal Transplantation
Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation
The purpose of the study is to evaluate the long term vascular morbidity and mortality in kidney transplant recipients based on one year post transplant levels of intact parathyroid hormone.
- Trial name
- SHPT-RT (NCT01741064)
- Volunteers
- 257 people
- Sponsor
- Skane University Hospital
Chronic Kidney Failure, Secondary Hyperparathyroidism
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
- Trial name
- PROTECT (NCT01083186)
- Where
- 24 sites in Greece
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Renal Osteodystrophy
12-month Study of AMG 073 in Renal Osteodystrophy
4 doses of AMG 073 or placebo over 52 weeks after a 30-day screening period. Throughout the study, labs will be drawn to measure analytes such as iPTH and corrected calcium.
- Trial name
- NCT00527085
- Testing
- AMG 073
- Volunteers
- 45 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, Renal Osteodystrophy
Regulation of Bone Formation in Renal Osteodystrophy
To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure
- Trial name
- NCT00560300
- Testing
- 1 alpha D2, 1,25 dihydroxy vitamin D3, Sevelamer HCl
- Volunteers
- 61 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Osteopenia, Renal Osteodystrophy
Osteopenia and Renal Osteodystrophy: Evaluation and Management
The purpose of this study is to demonstrate whether pamidronate will preserve or increase bone mass in patients with adynamic bone disease, caused by low bone turnover.
- Trial name
- NCT00108394
- Testing
- pamidronate
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Hyperparathyroidism; Secondary, Renal
Preemptive and Precise Intervention for CKD-SHPT
Through multi-center randomized controlled trial studies on preemptive surgical intervention in patients with chronic kidney disease (CKD) - secondary hyperparathyroidism (SHPT), to precisely evaluate the safety and effectiveness…
- Trial name
- NCT04523974
- Testing
- Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01651000
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- OPKO IP Holdings II, Inc.
End Stage Renal Disease
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage…
- Trial name
- NCT00113958
- Testing
- Cinacalcet
- Sponsor
- Amgen
Vitamin D Deficiency
Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder
It is hypothesised that the efficacy and safety of Vitamin D2 soft capsule to treat the Chronic Kidney Disease Mineral and Bone Disease (CKD-MBD) are equal to 1,25(OH)2 Vitamin D3 (Rocaltrol) in the patients with CKD stage 3-5.
- Trial name
- NCT01633853
- Testing
- Vitamin D2, 1,25(OH)2 Vit D3
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Dongliang Zhang, MD
Hyperparathyroidism, Secondary
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
- Trial name
- NCT01788046
- Testing
- Etelcalcetide
- Where
- 106 sites in United States, Australia and 13 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End Stage Renal Disease
Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism
This study was performed to determine whether calcitriol provides a therapeutic advantage to alfacalcidol for treatment of secondary hyperparathyroidism in ESRD patients.
- Trial name
- NCT01115543
- Testing
- alfacalcidol and calcitriol
- Where
- Thailand
- Volunteers
- 32 people
- Sponsor
- Mahidol University
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
Chronic Kidney Disease, Secondary Hyperparathyroidism
Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease
Active forms of vitamin D and its analogs are used to treat elevated parathyroid hormone levels and bone disease in chronic kidney disease (CKD).
- Trial name
- NCT01426724
- Testing
- Contrast Enhanced Ultrasonography
- Where
- United States
- Sponsor
- University of Virginia
Renal Osteodystrophy
Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function
The aim of the study is to 1. To describe the bone morphology in patients with reduced renal function and high or low parathyroid hormone (PTH) respectively. 2.
- Trial name
- NCT03716128
- Testing
- 18F-PET
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Ditte Hansen
Osteoporosis, Chronic Kidney Disease Mineral and Bone Disorder
Osteoporosis & Renal Disease: Research in Primary Health Care Services
Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures.
- Trial name
- NCT07848490
- Testing
- Fracture risk assessment tool (FRAX), Dual-Energy X-ray Absorptiometry (DXA)
- Where
- Portugal
- Volunteers
- 622 people
- Sponsor
- Universidade do Porto
Renal Osteodystrophy
Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation
The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.
- Trial name
- NCT01675089
- Testing
- Zoledronic acid
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo General Hospital
Secondary Hyperparathyroidism
Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)
Twelve-month, multicenter, intra-subject controlled (retrospective-prospective), open-label, active-treatment study to evaluate the dose-response and pharmacokinetics (PK) of cinacalcet HCl for the treatment of Secondary…
- Trial name
- NCT01479088
- Testing
- Cinacalcet HCl
- Where
- 5 sites in Italy
- Volunteers
- 30 people
- Sponsor
- ENRICO VERRINA
Hyperparathyroidism, Disorders of Parathyroid Gland
Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
It is difficulty for the treatment of secondary hyperparathyroidism in the chronic kidney disease (CKD) patients who had not succeeded medical therapy and could not get parathyroidectomy.
- Trial name
- NCT01640184
- Testing
- Parathyroidectomy, Active vitamin D, Ultrasonic ablation
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Dongliang Zhang, MD